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ABSTRACT
Background and Objectives: Recent studies have shown that sodium-glucose co-transporter 
2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and 
mortality in patients with diabetes. However, it is not clear whether SGLT2 inhibitors have 
a cardiovascular benefit in patients without diabetes. We aimed to determine whether 
empagliflozin (EMPA), an SGLT2 inhibitor, has a protective role in HF without diabetes.
Methods: Cardiomyopathy was induced in C57BL/6J mice using intraperitoneal injection of 
doxorubicin (Dox). Mice with HF were fed a normal chow diet (NCD) or an NCD containing 
0.03% EMPA. Then we analyzed their phenotypes and performed in vitro experiments to 
reveal underlying mechanisms of the EMPA's effects.
Results: Mice fed NCD with EMPA showed improved heart function and reduced fibrosis. In 
vitro studies showed similar results. Phloridzin, a non-specific SGLT inhibitor, did not show 
any protective effect against Dox toxicity in H9C2 cells. SGLT2 inhibitor can cause increase 
in blood ketone levels. Beta hydroxybutyrate (βOHB), which is well known ketone body 
associated with SGLT2 inhibitor, showed a protective effect against Dox in H9C2 cells and in 
Dox-treated mice. These results suggest elevating βOHB might be a convincing mechanism 
for the protective effects of SGLT2 inhibitor.
Conclusions: SGLT2 inhibitors have a protective effect in Dox-induced HF in mice. This 
implied that SGLT2 inhibitor therapy could be a good treatment strategy even in HF patients 
without diabetes.
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INTRODUCTION
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic 
agents that improve glycemic control, and reduce body weight and blood pressure, as a 
monotherapy or in combination with other diabetes medication. Recent studies have shown 
that SGLT2 inhibitors reduce the risk of cardiovascular-related death and heart failure (HF) 
hospitalization in patients with type 2 diabetes.1) It has been proposed that SGLT2 inhibitors 
have several direct or indirect effects that prevent the progression of HF. Increased osmotic 
diuresis, reduced sympathetic tone, and whole-body metabolic shift from glucose to fat 
oxidation caused by SGLT2 inhibition might explain the cardiovascular benefits, in addition 
to its blood glucose-lowering effects.2)
Patients with type 2 diabetes have shown elevated serum ketone body levels after SGLT2 
inhibitor treatment.3) SGLT2 inhibition promotes ketone utilization as an energy source in 
the heart and this shift might provide an energy advantage to the failing heart.4) The ketone 
body beta hydroxybutyrate (βOHB) is one of major metabolites (acetoacetate, acetone, and 
βOHB) from liver by fatty acid oxidation.5) βOHB increases cardiac work efficiency and shows 
protective effects by reduces oxidative stress in several animal studies.6)7)
Interestingly, SGLT2 inhibitors also increase glycosuria and reduce body weight in non-
diabetic subjects, and these subjects without diabetes also showed elevated serum ketone 
body levels.8)9) Therefore, we postulated that SGLT2 inhibitors would have beneficial effects 
on non-diabetic patients with congestive HF.
To test this hypothesis, we constructed a HF model in mice using doxorubicin (Dox). Dox 
is an effective anti-tumor drug that is widely used to inducing HF in animal studies.10) 
Dox-induced cardiotoxicity is characterized by left ventricular dysfunction and cardiac 
hypertrophy, which lead to congestive HF. We fed a normal chow diet (NCD) containing an 
SGLT2 inhibitor, empagliflozin (EMPA), to Dox-treated mice and examined their cardiac 
function, and their molecular and histological phenotypes.
METHODS
Chemicals and reagents
Dox hydrochloride (D1515), phloridzin dihydrate (P3449), and βOHB (54920) were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). EMPA (Boehringer Ingelheim, Ingelheim am 
Rhein, Germany) is a potent SGLT2 inhibitor. We made the EMPA diet by mixing EMPA in 
NCD (Harlan Teklad, Madison, WI, USA) at a concentration 300 mg/kg of diet.
Animals
Male C57BL/6J (B6J) mice were purchased from the Institute of Medical Science, University 
of Tokyo. The mice were housed at ambient temperature (22±1°C) in a specific pathogen-free 
facility under a 12 hours light-dark cycle. All diets and water were provided ad libitum. The 
serum βOHB levels of mice were measured using a βOHB Colorimetric Assay kit (Cayman 
Chemical, Ann Arbor, MI, USA) according to the manufacturer's protocol. All experiments 
were performed in accordance with relevant guidelines and regulations. Our animal protocol 
was designed to minimize pain and discomfort to the mice. For euthanasia, mice were 
continuously exposed to isoflurane during tissue sampling. All animal procedures were 
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approved by the Institutional Animal Care and Use Committee of CHA University (IACUC No. 
160033, 170047). Our study did not involve human data or tissue.
Dox-induced cardiomyopathy experiment
We constructed acute cardiomyopathy and chronic cardiomyopathy mouse models as 
previously described.11) Male B6J mice (8-weeks-old, weighting 22–24 g) were randomly 
divided into 4 groups. Control group: B6J mice (n=5) were fed an NCD with phosphate-
buffered saline (PBS) injection. EMPA group: B6J mice (n=5) were fed the EMPA diet with 
PBS injection. Dox group: B6J mice (n=5) were fed an NCD with Dox injection. Dox+EMPA 
group: B6J mice (n=5) were fed the EMPA diet with Dox injection. Acute cardiomyopathy 
was induced in the B6J mice by a single intraperitoneal (IP) injection of Dox (15 mg/kg). 
Diets were changed at night, 12 hours before PBS/Dox injection. To analyze the phenotype of 
these mice, all mice were sacrificed 2 weeks later. Chronic cardiomyopathy was induced by 
administering Dox at 2.5 mg/kg every other day for 12 days (cumulative dose=15 mg/kg). All 
mice were sacrificed 6 weeks later.
Mouse magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) was performed to assess the structural and 
functional changes in mice hearts by Dox-induced cardiotoxicity. Male B6J mice (10-weeks-
old, n=5 per each group) were examined using a Mouse Agilent 9.4 Tesla MRI Scanner 
(Agilent Technologies, Santa Clara, CA, USA). Heart sizes were measured using Image J 
software and functional parameters were calculated as previously described.12)
Cell culture and materials
H9C2 cells (rat cardiac myoblasts) were purchased from the Korean Cell Line Bank (21446) 
and maintained in high glucose Dulbecco's modified Eagle's medium supplemented with 
10% fetal bovine serum and 100 U penicillin/streptomycin. Cells were treated with various 
concentration of Dox (ranging from 0.1 to 10 µM) and tested after 12 hours or 24 hours. Dox 
and Phloridzin dihydrate were dissolved in dimethyl sulfoxide (DMSO). DMSO was used as a 
control vehicle.
Cytotoxicity assay and adenosine triphosphate assay
The cytotoxic effects of Dox and protective effects of other drugs in vitro on H9C2 cells 
were measured as previously described.13) The viability of H9C2 cells were analyzed using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide based colorimetric assay using 
a Cell Proliferation Kit I (Sigma-Aldrich). Adenosine triphosphate (ATP) was measured using 
ATPLite Luminescence Assay System (PerkinElmer, Waltham, MA, USA).
Determination of mitochondrial membrane potential and reactive oxygen 
species
Mitochondrial membrane potential (MPP) and reactive oxygen species (ROS) were measured 
as previously described.14) To measure the MPP and ROS, H9C2 cells were preincubated 
βOHB for 2 hours, and then with Dox for 12 hours in serum free media. For mitochondrial 
analysis, H9C2 cells were incubated for 30 minutes with 50 nM tetramethylrhodamine 
methyl ester (TMRM; Sigma-Aldrich). TMRM fluorescence images were obtained 
using confocal microscopy (Leica TCS SP5 II). Intracellular ROS were measured using 
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) (Thermo Fisher Scientific, Waltham, 
MA, USA).
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RNA isolation and quantitative real-time reverse transcription polymerase 
chain reaction
Total RNA was extracted using the TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer's protocol. For complementary DNA synthesis, total RNA (1µg) was 
reverse transcribed with the Qiagen Quantitect Reverse Transcription Kit (Qiagen, Hilden, 
Germany) according to the manufacturer's protocols. Quantitative real-time polymerase 
chain reaction (PCR) was performed using a FastStart Essential DNA Green Master kit (Roche 
Life Sciences, Indianapolis, IN, USA). The primer sequences are provided in Supplementary 
Table 1.
Western blot analysis
Heart tissue lysates and whole-cell lysates were used for western blotting analysis. Proteins 
were separated by electrophoresis and transferred to membranes. The membranes were 
incubated with specific primary antibodies (1:1,000) recognizing β-actin (#4970), cleaved-
caspase 3 (#9664), and C/EBP homologous protein (CHOP; #5554), purchased from Cell 
Signaling Technology (Danvers, MA, USA). The membranes were washed with Tris-buffered 
saline containing 0.05% Tween 20 and incubated with horseradish peroxidase-linked anti-
rabbit immunoglobulin G (IgG) antibody (1:2,000; AP188p) or anti-mouse IgG antibody 
(1:2,000; AP160P) from Sigma-Aldrich. Signals were captured using a ChemiDoc MP system 
(Bio-Rad, Hercules, CA, USA). Densitometric analysis was performed using Image J software.
Histological analysis
Mouse hearts were harvested, fixed in 4% paraformaldehyde in PBS, dehydrated, and 
embedded in paraffin. Then, 5-µm-thick tissue sections were deparaffinized and stained 
with hematoxylin and eosin (H&E). Fibrosis was detected with Masson's trichrome staining 
(Abcam, Cambridge, UK) according to the manufacturer's protocol.
Statistical analysis
Data are presented as mean±standard error of mean. Differences between groups were 
evaluated for statistical significance using Student's t-test or 1-way analysis of variance 
followed by Tukey's post hoc text. The p values <0.05 were considered significant.
RESULTS
An sodium-glucose co-transporter 2 inhibitor attenuates Dox-induced 
cardiomyopathy in mice
To test our hypothesis that EMPA might improve cardiac function in HF, we induced cardiac 
toxicity in mice by Dox administration and then fed them with an EMPA diet. We divided 
these mice into 4 groups: control group, EMPA group, Dox group, and Dox+EMPA group. 
Two weeks after Dox/vehicle injection, the left ventricles (LVs) of the mice in these 4 groups 
were examined to analyze the effects of EMPA on mouse hearts. To evaluate whether EMPA 
protects against Dox-induced cardiomyopathy, functional analysis was performed by 
heart MRI. In the acute stage, Dox causes cardiac hypertrophy in mice.15) The Dox+EMPA 
group showed body weight reduction after 2 weeks treatment but this change was not 
significant (Supplementary Figure 1). After 2 weeks of Dox treatment, mouse hearts showed 
hypertrophic changes (Figure 1A and B). As expected, EMPA reduced these pathological 
changes. The Dox+EMPA group displayed significantly reduced LV mass and improved fractional 
shortening compared with the Dox group (Figure 1B and C, Supplementary Figure 2). Masson's 
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trichrome staining revealed that EMPA reduced perivascular and interstitial fibrosis in mouse 
hearts treated with Dox (Figure 1D-F and Supplementary Figure 3). These results suggested 
that the SGLT2 inhibitor protects against Dox-induced cardiac toxicity in vivo.
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Figure 1. The SGLT2 inhibitor protects against Dox-induced cardiac toxicity. (A) Representative images of Dox-mediated changes in cardiac structure and function 
from cardiac MRI. (B) and (C) The Dox+EMPA group showed reduced LV mass, decreased LVESD, and improved FS compared with the Dox group. (D) Masson's 
trichrome stained cross-sections of mice, 2 weeks after single Dox injection. (E) Representative images of LV sections stained with H&E and with Masson's 
trichrome. The Dox+EMPA group showed less myocardial damage. (F) Quantification of interstitial fibrosis. Scale bar=50 μm. Each bar represents mean±standard 
error of mean. 
Dox = doxorubicin; EF = ejection fraction; EMPA = empagliflozin; FS = fractional shortening; H&E = hematoxylin and eosin; LV = left ventricle; LVEDD = left 
ventricular end diastolic diameter; LVESD = left ventricular end systolic diameter; MRI = magnetic resonance imaging; SGLT2 = sodium-glucose co-transporter 2. 
*p<0.05.
Beta hydroxybutyrate protects against Dox-induced cardiotoxicity in vitro
We observed that an SGLT2 inhibitor has protective effects against Dox-induced cardiac 
injury in vivo. However, the exact mechanism underlying the cardio-protective effect of 
SGLT2 inhibitors is still unclear. The SGLTs are present in heart. However, the major SGLT is 
SGLT1, not SGLT2.16)
We checked the expression of Sglt genes in the mouse heart. As expected, Sglt1 is expressed 
in both the kidney and LV. However, Sglt2 gene expression was very low in the LV compared 
with its expression in the kidney (Figure 2A and B). To investigate the direct effect of SGLT 
in the heart, we treated H9C2 cells with phloridzin (PHL), a non-selective SGLT inhibitor. 
After 2 hours of pretreatment with PHL, H9C2 cells were incubated with Dox for 24 hours. 
As shown in Figure 2C and D, cell viability was significantly reduced after Dox treatment and 
PHL pretreatment did not show a protective effect on Dox-induced cytotoxicity. These results 
suggested that SGLT has no direct role in cardiomyocytes during Dox-induced cardiotoxicity.
We focused on βOHB, a ketone body that is increased in the blood after SGLT2 inhibition, 
even in non-diabetic conditions.9)17)18) First, we treated H9C2 with βOHB at various 
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Figure 2. The SGLT inhibitor protects cardiomyocytes by increasing βOHB. (A) and (B) Sglt1 and Sglt2 mRNA expression in mouse LV and kidney by qRT-PCR. (C) 
Representative light microscopic images of H9C2 cells. H9C2 cells were stimulated with 5 μM Dox or pre-treated with PHL or βOHB for 2 hours and then treated 
with 5 μM Dox for 24 hours. (D) H9C2 cell viability of the PHL pre-treatment group by an MTT assay. (E) H9C2 cell viability of the βOHB pre-treatment group by 
an MTT assay. βOHB group showed improved cell viability under 1 μM Dox-induced cardiotoxicity compared to non-treated group. Scale bar=50 μm. Each bar 
represents mean±standard error of mean. 
βOHB = beta hydroxybutyrate; Dox = doxorubicin; LV = left ventricle; mRNA = messenger RNA; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; PHL = phloridzin; qRT-PCR = quantitative real-time reverse transcription polymerase chain reaction; SGLT = sodium-glucose co-transporter. 
*p<0.05 vs. Dox-treated group.
concentrations (100 μM, 1 mM, 10 mM, and 30 mM) according to previous studies.18)19) As 
shown in Figure 2C and E, βOHB pretreatment had significant protective effects against Dox-
induced cardiotoxicity.
Beta hydroxybutyrate reduces reactive oxygen species and improves 
mitochondrial function
Increased free radical production is the major mechanism of Dox-induced cardiac injury.20) 
Therefore, we measured intracellular ROS generation in H9C2 cells using H2DCFDA. 
H9C2 cells produced ROS after the addition of 5 μM Dox. However, when H9C2 cells were 
pretreated for 2 hours with βOHB, Dox-induced ROS production was significantly decreased 
(Figure 3A and B, Supplementary Figure 4). We then performed a western blotting assay to 
detect cell stress markers. We found that the levels of both cleaved caspase 3 and CHOP were 
increased after Dox treatment. In contrast, βOHB pretreatment suppressed the levels of these 
proteins (Figure 3C and D).
Dox treatment also induces mitochondrial dysfunction in cardiomyocytes.21) So, we measured 
the ATP levels after βOHB treatment. As expected, βOHB significantly increased intracellular 
ATP levels in H9C2 cells (Figure 3E). We then analyzed the MPP of Dox-treated H9C2 cells using 
TMRM fluorescent probe. Dox-treated H9C2 cells showed decreased uptake of TMRM. βOHB 
pretreatment restored the uptake of TMRM in H9C2 cells. These results suggested that βOHB 
protects cardiomyocytes from Dox-induced mitochondrial dysfunction (Figure 3F and G).
An sodium-glucose co-transporter 2 inhibitor protects the heart by 
increasing beta hydroxybutyrate levels
Collectively, these in vitro results suggested that the cardio-protective effects of SGLT2 
inhibition depend on elevated serum βOHB. We measured serum βOHB levels of our 4 
groups of mice after 2 weeks of treatment. As expected, the βOHB level was elevated in 
EMPA diet-fed groups (EMPA and Dox+EMPA) (Figure 4A). We then examined whether the 
EMPA diet reduced Dox-induced ROS generation in the mouse heart in vivo. We analyzed 
antioxidant gene expression in the LVs from the 4 groups of mice. In the qPCR analysis, the 
Dox treated LVs showed reduced anti-oxidative gene expression and the EMPA diet restored 
this suppression induced by Dox treatment (Figure 4B).
We then investigated whether βOHB could reduce Dox-induced cardiomyopathy in vivo. After 
a single IP injection of Dox (15 mg/kg), mice were injected with saline or βOHB (20 mmoL/
kg), according to a previously described method.22) After 2 weeks of IP injection, mice were 
sacrificed, histological analysis showed preserved myofibril structure and reduced cardiac 
fibrosis in the LVs of mice treated with Dox+ βOHB compared with that in the LVs of mice 
treated with Dox (Figure 4C and Supplementary Figure 5).
In addition, we investigated whether EMPA could inhibit Dox-induced chronic structural 
changes, such as eccentric hypertrophy in the heart. We fed the EMPA diet to Dox-treated 
mice and sacrificed them 6 weeks after the last injection, as previously described.23) After 
6 weeks of Dox injection, the hearts of Dox treated mice showed dilated cardiomyopathy 
(increased size and eccentric hypertrophy) (Figure 4D). The hearts of the EMPA diet-fed mice 
retained a similar size and structure to those of the control mice. Histological analysis also 
showed preserved myofibril structure and reduced cardiac fibrosis in the LVs of mice fed with 
Dox+EMPA compared with those of mice fed with Dox (Figure 4E). Collectively, these results 
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Figure 3. βOHB reduces ROS and improves mitochondrial function. (A) Representative confocal fluorescence images of H9C2 cells after Dox treatment. Higher 
level of ROS was detected by H2DCFDA staining (green fluorescence). (B) Quantification of intracellular ROS levels. βOHB reduced ROS of H9C2 cells with Dox. 
(C) Representative images of western blotting of cleaved caspase 3 and CHOP. (D) Densitometry analysis of immunoreactive bands of cleaved caspase 3. βOHB 
reduced cleaved caspase 3 expression of H9C2 cells with Dox. (E) Intracellular ATP was measured using a firefly-based ATP assay kit. Calculated ATP contents 
were normalized to the total protein content. Data are shown relative to ATP levels of the control (non-treated H9C2 cells). βOHB (1mM) increased ATP production 
compared to control. (F) Representative confocal fluorescence images of H9C2 cells stained with TMRM fluorescence probe (red fluorescence). (G) Quantification 
of TMRM fluorescence. βOHB restored TMRM intensity of H9C2 cells with Dox. Scale bar=50 μm. Each bar represents mean±standard error of mean. 
ATP = adenosine triphosphate; βOHB = beta hydroxybutyrate; CHOP = C/EBP homologous protein; DCF = 2′,7′-dichlorofluorescin; Dox = doxorubicin; H2DCFDA = 
2′,7′-dichlorodihydrofluorescein diacetate; ROS = reactive oxygen species; TMRM = tetramethylrhodamine methyl ester. 
*p<0.05; †p<0.01.
suggested that elevation βOHB by SGLT2 inhibition attenuated the oxidative stress induced 
by Dox treatment in mice.
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Figure 4. The SGLT2 inhibitor protects the heart by increasing βOHB. (A) Serum βOHB levels of mice, 2 weeks after single Dox (15 mg/kg) or saline injection. EMPA 
increased Serum βOHB levels of mice in both Control and Dox treated mice. (B) mRNA expression of FoxO3a, Sod2, and Cat (encoding catalase) in LV tissues of 
mice after single Dox or saline injection. EMPA increased these genes expression in LV tissues of mice with Dox. (C) Representative images of LV sections stained 
with H&E and with Masson's trichrome. Mice were injected daily with βOHB intraperitoneally after single Dox injection for 14 days. (D) Gross anatomical changes 
of Dox-treated hearts in a chronic model. (E) Representative images of LV sections stained with H&E and with Masson's trichrome. (F) A proposed model for the 
cardioprotective effect of the SGLT2 inhibitor against Dox-induced HF. Heart image was obtained and modified from Pixabay 2017 (https://pixabay.com/en/heart-
human-heart-anatomy-medicine-2028154). Scale bar=50 μm. Each bar represents mean±standard error of mean. 
βOHB = beta hydroxybutyrate; Dox = doxorubicin; EMPA = empagliflozin; H&E = hematoxylin and eosin; HF = heart failure; LV = left ventricle; mRNA = messenger 
RNA; ROS = reactive oxygen species; SGLT2 = sodium-glucose co-transporter 2. 
*p<0.05.
DISCUSSION
SGLT2 inhibitors have shown beneficial effects on HF patients with type 2 diabetes.24) Our 
study was designed to investigate the role of SGLT2 inhibitors in the development of Dox-
induced HF in mice, which is a well-known non-diabetic HF animal model. We demonstrated 
that the SGLT2 inhibitor attenuated Dox-induced cardiomyopathy in mice. Dox-treated 
mouse hearts showed cardiac hypertrophy and myocardial fibrosis, and the EMPA diet-fed 
mice showed reduced Dox-induced cardiomyopathy in acute (Figure 1D and E) and chronic 
models (Figure 4D and E).
EMPA-fed mice showed increased serum βOHB levels compared with NCD-fed mice (Figure 4A). 
These changes in non-diabetic mice after EMPA treatment are consistent with recent clinical 
data from humans.9) As expected, βOHB improved cell viability (Figure 2C) and reduced ROS 
generation (Figure 3A) in Dox-treated H9C2 cells. Recent study supported these results about 
anti-oxidant properties of βOHB.25) βOHB also improves mitochondrial function and increases 
ATP production in pancreatic beta cells and neuronal cells.26)27) In line with these findings, we 
found that βOHB increased intracellular ATP levels and restored mitochondrial dysfunction in 
cardiomyocytes (Figure 3E and F).
Several studies support our findings about the cardioprotective role of βOHB. Ketone bodies 
are effective energy source of failing heart and increase survival in aging mice.26)28) Exogenous 
βOHB infusion protects ischemic injury in heart by reducing ROS and enhancing adenosine 
trisphosphate production.29) These findings led us to speculate that ketone bodies have 
critical role in maintaining heart function and SGLT2 inhibitor acts indirectly on the heart by 
increasing blood βOHB levels.
We found that βOHB attenuated Dox-induced cardiotoxicity in vitro. However, in vivo, 
βOHB supplementation reduced Dox-induced myofibrillar loss and cardiac fibrosis at the 
microscopic level (Figure 4C) but did not demonstrate significant improvement in the gross 
morphological changes caused by Dox (Supplementary Figure 6). These results suggested 
that metabolic and hemodynamic effects of SGLT2 inhibitors, such as improved glucose 
homeostasis, lowering of blood pressure and weight loss, also have additional protective 
effects on heart function.2)
In summary, our study showed that an SGLT2 inhibitor could reduce Dox-mediated LV 
dysfunction. This protective effect is mediated by elevated βOHB levels. During SGLT2 
inhibition, elevated βOHB levels attenuated ROS production and improved mitochondrial 
dysfunction in cardiomyocytes (Figure 4F). Our findings suggested that cardioprotective role 
of SGLT2 inhibitor indicates a new strategy to prevent HF in patients receiving Dox.
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SUPPLEMENTARY MATERIALS
Supplementary Table 1
Primer list for real-time PCR
Click here to view
Supplementary Figure 1
Body weight change after 14 days of treatment.
Click here to view
Supplementary Figure 2
FS and EF changes after 1 week Dox treatment. The EMPA group improved FS and EF 
compared with Control group. The Dox+EMPA group also showed improved FS and EF 
(p=0.06) compared with Dox group.
Click here to view
Supplementary Figure 3
H&E and Masson's trichrome stained microscopic images of Dox and Dox+EMPA treated 
heart (scale bar=100 um).
Click here to view
Supplementary Figure 4
The effect of Dox and βOHB on ROS generation using DCFDA assay in confocal microscopy 
(green: H2DCFDA, scale bar=50 um).
Click here to view
Supplementary Figure 5
H&E and Masson's trichrome stained microscopic images of Dox and Dox+βOHB treated 
heart (scale bar=100 µm).
Click here to view
Supplementary Figure 6
Gross images of Dox and Dox+βOHB treated heart.
Click here to view
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